Roivant Sciences Ltd. (NASDAQ: ROIV) reported a quarterly loss of $0.23 per share for the period ending March 2024, slightly better than the Zacks Consensus Estimate of a loss of $0.25 but worse than a loss of $0.20 per share a year prior, representing an 8% earnings surprise. The company has surpassed consensus EPS estimates three times over the last four quarters.
Montes Archimedes Acquisition, another player in the medical – biomedical and genetics sector, generated revenues of $28.93 million during the same quarter, falling short of estimates by 10.86% and increasing from $27.38 million in the previous year. The company’s stock has declined about 4.5% year-to-date, underperforming the S&P 500, which has gained 10.4%. Looking ahead, consensus EPS estimates are -$0.21 on revenues of $56.64 million for the upcoming quarter.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
